Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Manhattan Associates Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.28 (market cap $12.58B), while Manhattan Associates Inc trades at $204.74 (market cap $12.06B). The key difference: Halozyme Therapeutics Inc. Common Stock and Manhattan Associates Inc are close in size by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Manhattan Associates Inc for 12 Days on average.
| HALO | MANH | |
|---|---|---|
Market Cap | $12.58B | $12.06B |
Volume | 2,179,278 | 376,150 |
Sector | Health | Technology |
52-Week High | $115.22 | $223.76 |
52-Week Low | $61.63 | $120.88 |
Typical Hold Time | 1 Days | 12 Days |
Enterprise Value | $14.49B | $11.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Manhattan Associates (MANH) trades at $202.11, down 0.36% with bearish technical signals but strong fundamentals. The stock shows robust profitability with 18.67% net margins and consistent earnings beats, though valuation multiples appear elevated. Recent news includes a law firm investigation into fiduciary duties and a downgrade to neutral by DA Davidson, while the company launched new solution editions to expand market reach.
The outlook balances strong operational performance against high valuation and legal scrutiny. Upside potential exists from continued earnings momentum and product innovation, but risks include the ongoing investigation and competitive pressures. Analyst consensus remains bullish with a $210.50 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
